Charles Foucar, MD
Hematology · Ann Arbor, MINPI 1912325887
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,350 of the $10,829 with a category attached, or 95.6%. 6 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 52.9% of the total.
Across 8 payments — averaging $1353.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- Taiho Oncology, Inc.$3K
- Stemline Therapeutics Inc.$2K
- Janssen Research & Development, LLC$146
- Bristol Myers Squibb$135
- Genentech USA, Inc.$74
Across 10 payments — averaging $81,948 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$723K
- Janssen Research & Development, LLC$70K
- E.r. Squibb & Sons, L.L.C.$27K
What the payments were for
- Consulting fees$10,35096%
- Food & beverage$4794%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $5,730 |
| Taiho Oncology, Inc. | 2 | $2,573 |
| Stemline Therapeutics Inc. | 1 | $2,170 |
| Janssen Research & Development, LLC | 1 | $146 |
| Bristol Myers Squibb | 1 | $135 |
| Genentech USA, Inc. | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,829 in reported general payments places this provider in the 75th percentile of 50 hematology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Allopurinol | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Other hematology in Ann Arbor
- Matthew PiankoAnn Arbor$51K
- Sami MalekAnn Arbor$49K
- Yasmin KarimiAnn Arbor$47K
- Kristen PettitAnn Arbor$45K
- Samuel SilverAnn Arbor$23K
- Jordan SchaeferAnn Arbor$14K
- Sarah AnandAnn Arbor$14K
- John MagenauAnn Arbor$13K
- Patrick BurkeAnn Arbor$6K
- Dale BixbyAnn Arbor$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.